Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G1OZ
|
||||
| Former ID |
DAP000898
|
||||
| Drug Name |
Mephentermine
|
||||
| Synonyms |
Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Maintain blood pressure in hypotensive states [ICD10:I10] | Approved | [1] | ||
| Therapeutic Class |
Vasoconstrictor Agents
|
||||
| Company |
Baxter Healthcare Corp Anesthesia Critical Care
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H17N
|
||||
| InChI |
InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
|
||||
| InChIKey |
RXQCGGRTAILOIN-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 100-92-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10091, 5152744, 7979903, 8152323, 10502228, 11112475, 11335404, 11360643, 11364505, 11367067, 11369629, 11372239, 11373874, 11377791, 11461615, 11466754, 11467874, 11484344, 11486327, 11488290, 11491035, 11492003, 11495425, 14772475, 29222800, 46505918, 47291289, 47810934, 47959942, 48185153, 48334678, 48334679, 48334680, 48416215, 49698940, 50004733, 50100459, 50100460, 57321934, 74493046, 96024870, 104304202, 118263315, 123085522, 124577122, 125822957, 126671824, 131342029, 132564025, 134222260
|
||||
| SuperDrug ATC ID |
C01CA11
|
||||
| SuperDrug CAS ID |
cas=000100925
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.